Topics:
Gastrointestinal Cancers • Medical Oncology
What systemic therapy would you offer a colon cancer patient after resection of oligometastatic disease that developed while on adjuvant therapy?
In a patient who developed oligometastatic disease before completing adjuvant XELOX, what treatment(s) and duration of treatment would you recommend?
Answer from: Medical Oncologist at Community Practice
Given that irinotecan has no proven efficacy in the adjuvant setting, there are two options in this case: 1) Continue XELOX to complete a 6 month course or 2) Active surveillance reserving further therapy for a time of disease recurrence. While the fact that the ovarian metastases developed while on...
Sign in or Register to read more